Milk thistle extracts have been used as traditional herbal remedies for almost 2000 years. The extracts are still widely used to protect the liver against toxins and to control chronic liver diseases. Recent experimental and clinical studies suggest that milk thistle extracts also have anticancer, antidiabetic, and cardioprotective effects. This article reviews clinical trials of milk thistle conducted in the past 5 years including pharmacokinetic and toxicity studies, herb-drug interactions, and other safety issues. Several trials have studied the effects of milk thistle for patients with liver diseases, cancer, hepatitis C, HIV, diabetes, and hypercholesterolemia. Promising results have been reported in the protective effect of milk thistle in certain types of cancer, and ongoing trials will provide more evidence about this effect. In addition, new established doses and improvement on the quality and standardization of this herb will provide the much-awaited evidence about the efficacy of milk thistle in the treatment of liver diseases. Milk thistle extracts are known to be safe and well tolerated, and toxic or adverse effects observed in the reviewed clinical trials seem to be minimal. The future of milk thistle research is promising, and high-quality randomized clinical trials on milk thistle versus placebo may be needed to further demonstrate the safety and efficacy of this herb.
A number of clinical trials of milk thistle (Silybum marianum [L.] Gaertn. [Asteraceae] ) and some of its components (flavonolignans) have been published in the past 15 years. The available evidence suggests that milk thistle (MT) extracts have an important hepatoprotective as well as anticancer, antidiabetic, and cardioprotective effect. However, high-quality clinical studies are limited, and very few have rigorously evaluated the purported anticancer and other pharmacological activities of this interesting herb. [1] [2] [3] [4] [5] [6] [7] [8] [9] The number is even smaller for pediatric trials and trials evaluating the safety of MT.
The most recent meta-analysis published by the Cochrane Collaboration 3 concludes that MT does not seem to significantly influence the course of the disease in patients with alcoholic and/or hepatitis B or C liver diseases. However, all-cause mortality was reduced by 50% in patients with alcoholic liver disease without hepatitis C virus (HCV) antibodies who took MT extracts compared to placebo (P < .05). 2, 3 The quality of these trials was low, 8 and it is difficult to say if the lack of information about MT efficacy reflects poor scientific quality of study methods, poor reporting quality, or both. 2, 3, 8 Despite negative reports, MT seems to have some effect in chronic liver diseases, particularly alcoholrelated liver disease, toxin-induced liver disease, and viral liver disease. The beneficial effect of MT in drug interactions is also noteworthy. The whole herb and its constituents may prevent nephrotoxicity associated with the use of acetaminophen, cisplatin, vincristine, and cyclosporine, as well as radiotherapy. [10] [11] [12] [13] [14] Nevertheless, researchers suggest that careful administration of silybin with drugs primarily cleared by CYP450s 3A4 or 2C9 would be advisable. 12 Recent clinical studies have addressed the effect of MT in the pharmacokinetics of other drugs such as digoxin, 15 indinavir, [16] [17] [18] rifampin, and erythromycin, 19 suggesting in general a lack of associated toxicity or interference in the metabolism of these commonly used conventional drugs. Several trials have reported the antitoxic effect of MT in preventing liver damage due to exogenous exposure to alcohol, drugs, occupational toxins, and toxic mushrooms. [20] [21] [22] [23] A randomized double-blind study on medical treatments for cirrhosis of the liver found a significantly higher survival rate among those suffering from alcoholic cirrhosis in the group treated with MT silymarin extract. 24 The authors attributed the results to the protective influence of this herb against toxic alcohol injuries.
One prospective clinical study on the protective effect of Legalon MT extract (Madaus, Cologne, Germany) in workers exposed to organic solvents documented a significant improvement in liver function test for those taking Legalon compared with those receiving no treatment. 22 Administration of silybin within approximately 48 hours after poisoning produced by the mushroom Amanita phalloides (death cap) seems to be an effective measure to prevent severe liver damage. 25 Combination of standard therapy along with silibinin produced a rapid resolution of clinical symptoms. 26 A retrospective analysis of 205 cases of clinical poisoning during 1971 to 1980 found positive results for MT's silybin extract in increasing survival rates for adults and children exposed to this potentially lethal mushroom. 27 In January 2007, 6 family members in California suffering from amatoxin poisoning, caused by Amanita phalloides mushrooms were treated with intravenous MT. The drug Legalon Sil® was provided by Madaus Pharma (Brussels, Belgium; division of Madaus AG, Cologne, Germany). The FDA granted permission to use MT after considering that all patients were going to die of liver failure. Only 1 of the 6 patients died, and all of the rest have had a full recovery after treatment (http://www.herbalgram.org:80/ default.asp? c= 8284ThistleMushroom).
A recent case report mentions that MT may offer protection from liver toxicity caused by the pharmaceutical drug phenytoin. 28 Clinical trials of the use of MT in diabetic patients, patients undergoing peritoneal dialysis, and patients with hypercholesterolemia are becoming more common. 29 Promising results also have been reported in the preventive effect of MT in cancer of the skin, 30, 31 colorectal cancer, 32 and other cancers. 33 Preclinical data suggest that the anticancer and antidiabetic effect is quite strong, but at this time, no definitive results confirm these effects, and more research has been recommended. [34] [35] [36] Several MT clinical trials are ongoing at this time. A large collaborative study is currently under way for treatment of hepatitis C. This study is funded by the National Center for Complementary and Alternative Medicine, the National Institute of Allergy and Infectious Diseases, and the National Institute of Diabetes and Digestive and Kidney Diseases. 37 Research updates are available online at www.nccam.nih.gov.
One study was recently completed, and another study is planned to evaluate the effects of MT to normalize and preserve liver function in pediatric patients with acute lymphocytic leukemia (Elena Ladas, personal communication, November, 2006 38 ).
The anticancer preventive and therapeutic efficacy of silibinin is also being evaluated in a phase I clinical trial in prostate cancer patients. 39 In addition, manufacturing companies of MT extracts are also conducting clinical trials with their own products that will elucidate effects of specific preparations. These studies will increase both the quality and amount of efficacy and safety data about this herb.
Clinical studies of MT extracts generally have suffered from the same shortcomings found in many other trials of herbal medicines such as small sample size, lack of appropriate randomization, allocation concealment or blinding, very different periods of treatment, lack of information about type and dose of extract used as well as product characterization, illdefined patient population, and a lack of etiology, severity of disease, and discussion of potential confounders. Both methodological quality and reporting of MT are improving and will continue to improve if researchers in academia and industry follow available guidelines and regulatory requirements for properly conducting and reporting clinical trials. Recently an academic group led by researchers at the University of Toronto published guidelines to report results of randomized control trials (RCTs) of herbal medicines, adding to the already accepted Consolidated Standards of Reporting Trials (CONSORT) statement. 40, 41 There are also a number of regulatory guidelines available from different countries that will aid in the development of high-quality clinical trials using both a well-characterized, well-defined product and good clinical practices (see regulatory guidance references in appendix).
Major Findings From Current Clinical Trials
It is beyond the scope of this article to address MT efficacy in detail, particularly due to the variability of extracts and compounds tested in clinical trials as well as the availability of several reviews and metaanalyses of trials published in the past few years. This section addresses mainly clinical trials conducted in the past 5 years.
Detailed trial information and general conclusions are available in evidence-based reports, monographs, and several meta-analyses that have been published and are available from the Internet (Cochrane Collaboration, Natural Standard Database, American Herbal Pharmacopoeia, American Botanical Council, and others). A comprehensive list of clinical trials available up to 2003 is available in the HerbMed database (www.herbmed.org). Studies addressing the anticancer activity of MT, including cytotoxic and preventive effects, control of side effects of conventional treatments, and enhancing the efficacy of chemotherapeutic agents, have been reviewed elsewhere. 42 It is important to emphasize that RCTs are still the gold standard to evaluate both efficacy and safety of medical interventions. However, in general, RCTs are not designed or powered to pick up adverse events, nor are they long enough to detect long-term adverse effects. This is particularly true when adverse events are rare or uncommon. Therefore, information about the safety of MT reported here is limited to the authors' observations in available clinical trials.
A summary of general findings is provided below, and detailed trial information is available in Tables 1 to 3. For the clinical trials evaluated in this review, an attempt was made to determine compliance with the CONSORT statement as well as an evaluation of the quality of the trials using the Jadad Scale. 43 However, this was not possible because not all new trials are phase III (RCT) trials.
Phase I/II: Dose Finding, Pharmacodynamic, and Pharmcokinetic Studies
Several doses of MT (silymarin) have been tested both alone and in conjunction with other drugs in several populations. Up to 13 g, divided in 3 daily doses of silibinin phytosome (Siliphos®), was evaluated in prostate cancer patients and was determined as the recommended dose to further evaluate anticancer effects of silibin. 44 Dosages of 360, 720, or 1440 mg of silibinin daily for 7 days achieved high silibinin levels in the colorectal mucosa of 24 colorectal cancer patients after consumption of phosphatidylcholine (Silipide®). This finding may support further exploration of silibinin as a potential preventive agent for colorectal cancer. 32 Flavonoids from MT (ie, silibinin, Legalon) seem to normalize immunoregulatory defects via restoration of the cellular thiol status. T-cell activation (CD69), along with a significant decrease in TNF-α release (P < .05), was observed in 30 patients with end-stage diabetic nephropathy. 45 A bioavailability study of 3 silibinin-containing products (Liverman capsule, Legalon capsule, and silymarin tablet) suggested that Liverman capsules are better absorbed and have a greater bioavailability. 46 
Phase I/II: Herb-Drug Interaction Studies
Milk thistle does not seem to alter the disposition of anticancer drugs metabolized by the CYP3A4 and UGT1A1 enzymes, 47 and it does not affect indinavir levels in healthy individuals 17, 18 or in patients with HIV. 16 Milk thistle does not have clinically relevant effects on CYP3A activity 19 or CYP1A2, CYP2D6, and CYP2E1 activity 48 and does not interfere with P-glycoprotein (P-gp) modulation. 15 In testing the effect of silibinin on chemotherapy agents in vitro, silibinin at low doses (10 µM) caused no negative interactions with vincristine or L-asparaginase on a T cell acute lymphoblastic leukemia cell line. At higher concentrations (30 µM), silibinin was synergistic with vincristine and not with L-asparaginase. 49 
Phase III (Randomized Double-Blind Clinical Trials)
In a phase III RCT in cancer, a dietary supplement, containing silymarin, soy, lycopene, and antioxidants as the main ingredients, was shown to delay prostatespecific antigen progression significantly (P < .030) after prostatectomy and radiotherapy in prostate cancer patients. 50 In chronic hepatitis C virus (HCV) ( Table 3) , 373.5 mg of MT was safe and well tolerated for up to 1 year. 51 In a follow-up study, 420 mg daily did not prevent complications of HCV but improved general health and symptoms for up to 2 years. 52 Higher doses of 600 and 1200 mg/d were tolerated but had no significant effect on serum HCV ribonucleic acid titers (P = .52) and serum alanine aminotransferase (ALT) and other liver chemistries (P = .28) and did not improve quality of life or psychological well-being. 53 A small beneficial, but not significant, effect of MT was observed in patients with chronic hepatitis C on sustained biochemical response and virologic response. However, the clinical effect of interferon therapy was 10-fold greater than MT. 54 In another study, MT had an effect on liver chemistries but no apparent effect on viral load, suggesting that S marianum may have a protective effect in the inflammatory response to HCV but no role as an antiviral agent. 55 An open-label study of 50 patients testing MT and other antioxidants suggested that the combination may have a beneficial effect on necroinflammatory variables. 56 In hepatic cirrhosis, silymarin MZ-80 (S) did not produce any changes in routine liver test results, but it had an antiperioxidative effect in peripheral blood cells. 57 In patients with alcoholic liver disease and concomitant noninsulin-dependent diabetes mellitus, silybin-βcyclodextrin 135 mg daily did not change liver function test results or insulin secretion but significantly reduced fasting glucose (P < .03) and serum triglyceride levels (P < .01) compared to placebo. The effects seem to be through reduced glycosylated hemoglobin (HbA1c) levels and insulin sensitivity. 58 In an RCT of 51 type II diabetic patients, 600 mg daily MT over 4 months improved the glycemic profile compared to placebo, confirming reductions in HbA (1) CYP3 activity was affected by rifampin and clarithromycin. Pre-post supplementation phenotypic ratios suggest no effect of these supplements on CYP1A2, CYP2D6, CYP2E1, and CYP3A4 activity.
MT poses a minimal risk for CYPmediated herb-drug interactions in humans.
Quantities of flavonolignans were consistent with label claims of MT.
No significant effects on digoxin PK following supplementation with either MT or black cohosh, although digoxin AUC (0-3) and AUC (0-24) approached significance (P = .06) following MT.
Compared with rifampin and clarithromycin, these formulations of MT or black cohosh did not affect digoxin PK, suggesting that these supplements are not potent modulators of P-gp in vivo and do not pose a significant interaction risk with digoxin. In testing the efficacy of MT for functional dyspepsia, STW-5 (Iberogast), a combination of MT fruits and other 8 herbs, improved dyspeptic symptoms earlier than the herbs alone (without MT). The MT seed extract used in this combination is referred to by its German name as Cardui mariae fructus. 60
Safety Results in Control Trials
Milk thistle has been recognized as a "safe and well tolerated herb" with a limited adverse event profile usually reported to be similar to placebo. 2, 8, 61 Similar to other plant products commonly used as foods and herbs, MT extracts do not seem to lead to toxic Recommended dose is safe up to 2 years but no effect on outcomes.
No differences in SF-36 or RNA titers or ALT levels between groups.
Well tolerated but no effect on outcomes in this sample. NIFN-BT more effective than silymarin: 4-fold higher ETVR 10-fold higher SBR than silymarin Greater normalization of ALT (58.5% vs 15.3%) Viral response 2.4% vs 0% SBR 28% vs 2.8% SVR 2.4% vs 0% 
effects. However, a strict dose-dependency curve
has not yet been reported, and short-term trials of high silymarin intake have not been done in healthy populations.
The model commonly reflected in the safety data of clinical trials is the direct toxicity model, as opposed to a model of the potentiation of the toxicity of other drugs. It is not clear from the reviewed literature if this latter model has been evaluated in MT trials. Nevertheless, it seems clear that under the restricted conditions of available trials, MT appears to be quite safe.
The limitations of available clinical trials with regard to establishing safety are the same as they are with regard to establishing efficacy. Clinical trials testing safety very poorly predict the fate of extracts in realworld settings, where patients ingest multiple drugs and herbs, take different formulations of the same product, and add alcohol and other compounds, often for extremely extended periods.
For randomized trials reporting adverse effects, incidence was approximately equal in the MT and control groups. 53 The majority of adverse events observed were unrelated to the product or difficult to separate from the concomitant disease, and causality is rarely addressed in available reports. There is no safety data in children or older adults, as there were no reported studies in children and very few studied that included patients older than 65 years.
Adverse effects associated with oral ingestion of MT include mainly gastrointestinal problems, but these are rare. 9 Headache/dizziness and pruritus were reported in 1 trial. 53 Asymptomatic liver toxicity has been observed in recent clinical trials done in cancer patients, where hyperbilirubinemia and increases in ALT have been observed, but only with very high dosages of silybin-phytosome between 10 and 20 g daily. 44 At high doses (>1.5 g/d), a laxative effect is possible due to increased bile secretion and flow. Mild allergic reactions have also been noted but were not serious. 62 In an oral form standardized to contain 70% to 80% silymarin given at a dosage of 420 mg daily, MT appears to be safe for up to 41 months of use, and significant drug reactions have not been reported. 61
The Future of Milk Thistle Clinical Trials
The majority of researchers agree that more highquality clinical trials are needed to evaluate the hepatoprotective effect of MT in the course of liver diseases and in the hepatotoxicity produced by certain medications. A National Institutes of Health consensus conference on the management of hepatitis C held in 2002 concluded, "There is a need to assess the effectiveness of supportive therapy to ameliorate the side effects of antiviral therapy." In addition, "Trials are needed in combination therapy non-responders and those who cannot tolerate conventional therapies, comparing combinations of antifibrotic and anti-inflammatory agents, as well as immunomodulatory drugs and drugs that are directed specifically at HCV replication. Studies are also needed to assess the efficacy of alternative and nontraditional medicines." 63 Although not mentioned specifically, MT may be a good preventive and therapeutic intervention for hepatitis C and other liver diseases, including hepatobiliary obstruction and cholelithiasis, and should be further evaluated.
In addition, older trials reporting positive effects of MT in preventing liver damage due to exogenous exposures to alcohol, drugs, occupational toxins, and toxic mushrooms described above should be replicated with more appropriate designs.
Another evidence-based report prepared by the Agency for Healthcare Research and Quality evaluated the effects of MT on liver disease of alcohol, viral, toxin, cholestatic, and primary malignancy etiologies as well as clinical adverse effects associated with MT ingestion or contact. This report concludes that MT's efficacy is not well established. Survival and other clinical outcomes in RCTs have been inadequately evaluated or reported with mixed results. Future research should include definition of multifactorial mechanisms of action, well-designed clinical trials, and clarification of adverse effects. 7 According to other authors, future clinical studies in chronic hepatitis C should focus on the role of S marianum in combination with other herbal therapies in improving appropriate and reliable clinical and laboratory parameters in this condition. 53 No studies have evaluated MT for cholestatic liver disease or primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) or for combined use of MT with other hepatoprotective agents, although experimental studies on hepatocarcinoma cells (HCC) show promise in this area. 36 There are limited clinical trials evaluating choledolithiasis or cholangitis. Further clinical research in this area is warranted based on recent findings showing that silymarin modulates bile flow and bile salt secretion, exerts beneficial changes in overall bile salt metabolism, and has novel anticholestatic properties in experimental models of hepatocellular cholestasis, including those induced by estrogens and monohydroxylated bile salts. 1 Anticancer, antidiabetic activity, and the effects of MT phytoestrogens (flavonolignans) on estrogen metabolism, particularly on the occurrence of catechol-estrogen-quinones known to cause carcinogenic depurinating DNA adducts within cells, 64 also deserve further investigation.
